10 Best Weight Loss Drug Stocks to Buy in 2026
The article says the U.S. anti-obesity drug market is expanding, with the global GLP-1 market reaching $79B in 2025 and projected by Morgan Stanley to exceed $190B by 2035. It cites January 2026 oral Wegovy pill uptake and Medicare/Medicaid BALANCE plans to cap out-of-pocket costs at $50/month. It also notes DOJ scrutiny of compounded formulations and lists 10 stocks, including Altimmune (H.C. Wainwright cut ALT target to $20 from $25) and GSK.
How this was made
The 30-second read
Why it matters
For ALT, the newest concrete item is 48-week Phase 2b trial results for pemvidutide in MASH. For GSK, the newest concrete items are FDA approval of Utebzi and Orphan Drug Designation for momelotinib in VEXAS—pipeline positives but not directly obesity-specific in the provided excerpt.
Market read
This is more of a sector-and-stock roundup than a single decisive catalyst; it provides concrete trial/regulatory datapoints for two names but lacks fresh, tradable numbers like guidance, pricing, or deal terms.
What to watch
Key missing trading inputs include actual stock price reaction, trial primary endpoints/registrational path, dilution/financing details beyond a PT cut, and whether regulators’ compounded restrictions are finalized/timed.
Background
The article frames a rapidly evolving US anti-obesity drug market (oral GLP-1, Medicare/Medicaid cost caps, employer coverage) and then lists “best” weight-loss drug stocks.
Ticker impact
Altimmune reported new 48-week IMPACT Phase 2b results for pemvidutide in MASH, including cardiometabolic improvements vs placebo.
Moderate positive bias for near-term sentiment; magnitude depends on how investors weigh MASH endpoints and next trial steps.
The article cites specific 48-week outcomes (weight/BMI, lipids, BP, tolerability) and a congress presentation, which are concrete catalysts for biotech sentiment even without FDA/regulatory action.
GSK announced FDA approval of Utebzi for complicated UTI and Orphan Drug Designation for momelotinib in VEXAS syndrome.
Slight positive read-through for pipeline momentum; limited direct impact on obesity drug expectations from this specific text.
The obesity framing is broad, but the concrete regulatory events described are for anti-infectives and a rare disease indication, so the direct trading linkage to weight-loss is weaker.
Market effects
Highlights continued structural tailwinds for GLP-1/oral AOMs and tighter compounded-drug enforcement, supporting branded obesity drug demand.
Primarily US policy/coverage dynamics (Medicare/Medicaid cap, employer coverage) with potential spillover to US-listed AOM developers.
Mentions global market growth projections and EASL congress presentation, reinforcing international investor focus on obesity pipelines.
Counterpoint
The piece is a promotional “best stocks” list; most cited catalysts are not obesity-specific for every name and may already be partially known by the time of publication.
Key entities
- companyAltimmune, Inc.
Clinical-stage biopharma developing pemvidutide; reported 48-week IMPACT Phase 2b results in MASH.
- companyGSK plc
Biopharma; reported FDA approval of Utebzi and Orphan Drug Designation for momelotinib in VEXAS.
